mTOR inhibition in COVID-19: A commentary and review of efficacy in RNA viruses

Basil S. Karam; Rachel S. Morris; Carolyn T. Bramante; Michael Puskarich; Emily J. Zolfaghari; Sahar Lotfi-Emran; Nicholas E. Ingraham; Anthony Charles; David J. Odde; Christopher J. Tignanelli

doi:10.1002/jmv.26728

mTOR inhibition in COVID-19: A commentary and review of efficacy in RNA viruses

Basil S. Karam, Rachel S. Morris, Carolyn T. Bramante, Michael Puskarich, Emily J. Zolfaghari, Sahar Lotfi-Emran, Nicholas E. Ingraham, Anthony Charles, David J. Odde, Christopher J. Tignanelli

Research output: Contribution to journal › Comment/debate › peer-review

65 Scopus citations

Abstract

In this commentary, we shed light on the role of the mammalian target of rapamycin (mTOR) pathway in viral infections. The mTOR pathway has been demonstrated to be modulated in numerous RNA viruses. Frequently, inhibiting mTOR results in suppression of virus growth and replication. Recent evidence points towards modulation of mTOR in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We discuss the current literature on mTOR in SARS-CoV-2 and highlight evidence in support of a role for mTOR inhibitors in the treatment of coronavirus disease 2019.

Original language	English (US)
Pages (from-to)	1843-1846
Number of pages	4
Journal	Journal of Medical Virology
Volume	93
Issue number	4
DOIs	https://doi.org/10.1002/jmv.26728
State	Published - Dec 17 2020

Bibliographical note

Funding Information:
This study was supported by the Agency for Healthcare Research and Quality (AHRQ) and Patient‐Centered Outcomes Research Institute (PCORI), grant K12HS026379 (Christopher J. Tignanelli), the Minnesota Learning Health System Mentored Training Program (MH‐LHS), M Health Fairview Institutional Funds (Carolyn T. Bramante), the National Center for Advancing Translational Sciences, grants KL2TR002492 and UL1TR002494 (Carolyn T. Bramante), the National Heart, Lung, Blood Institute T32HL07741 (Nicholas E. Ingraham), COVID‐19 rapid response grant UM 2020‐2231. The work was supported by the University of Minnesota Institute for Engineering in Medicine Medtronic Professorship held by David J. Odde, and a COVID‐19 rapid response grant to David J. Odde from the University of Minnesota Medical School, as well as the National Institute of Health, grant U54‐CA210190 (David J. Odde).

Funding Information:
This study was supported by the Agency for Healthcare Research and Quality (AHRQ) and Patient-Centered Outcomes Research Institute (PCORI), grant K12HS026379 (Christopher J. Tignanelli), the Minnesota Learning Health System Mentored Training Program (MH-LHS), M Health Fairview Institutional Funds (Carolyn T. Bramante), the National Center for Advancing Translational Sciences, grants KL2TR002492 and UL1TR002494 (Carolyn T. Bramante), the National Heart, Lung, Blood Institute T32HL07741 (Nicholas E. Ingraham), COVID-19 rapid response grant UM 2020-2231. The work was supported by the University of Minnesota Institute for Engineering in Medicine Medtronic Professorship held by David J. Odde, and a COVID-19 rapid response grant to David J. Odde from the University of Minnesota Medical School, as well as the National Institute of Health, grant U54-CA210190 (David J. Odde).

Publisher Copyright:
© 2020 Wiley Periodicals LLC

Keywords

COVID-19
mTOR
mTORi

PubMed: MeSH publication types

Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1002/jmv.26728

Find It

Find It at U of M Libraries

Cite this

@article{65a40556f18749bab57d1d77bdb9d9b5,

title = "mTOR inhibition in COVID-19: A commentary and review of efficacy in RNA viruses",

abstract = "In this commentary, we shed light on the role of the mammalian target of rapamycin (mTOR) pathway in viral infections. The mTOR pathway has been demonstrated to be modulated in numerous RNA viruses. Frequently, inhibiting mTOR results in suppression of virus growth and replication. Recent evidence points towards modulation of mTOR in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We discuss the current literature on mTOR in SARS-CoV-2 and highlight evidence in support of a role for mTOR inhibitors in the treatment of coronavirus disease 2019.",

keywords = "COVID-19, mTOR, mTORi",

author = "Karam, {Basil S.} and Morris, {Rachel S.} and Bramante, {Carolyn T.} and Michael Puskarich and Zolfaghari, {Emily J.} and Sahar Lotfi-Emran and Ingraham, {Nicholas E.} and Anthony Charles and Odde, {David J.} and Tignanelli, {Christopher J.}",

note = "Funding Information: This study was supported by the Agency for Healthcare Research and Quality (AHRQ) and Patient‐Centered Outcomes Research Institute (PCORI), grant K12HS026379 (Christopher J. Tignanelli), the Minnesota Learning Health System Mentored Training Program (MH‐LHS), M Health Fairview Institutional Funds (Carolyn T. Bramante), the National Center for Advancing Translational Sciences, grants KL2TR002492 and UL1TR002494 (Carolyn T. Bramante), the National Heart, Lung, Blood Institute T32HL07741 (Nicholas E. Ingraham), COVID‐19 rapid response grant UM 2020‐2231. The work was supported by the University of Minnesota Institute for Engineering in Medicine Medtronic Professorship held by David J. Odde, and a COVID‐19 rapid response grant to David J. Odde from the University of Minnesota Medical School, as well as the National Institute of Health, grant U54‐CA210190 (David J. Odde). Funding Information: This study was supported by the Agency for Healthcare Research and Quality (AHRQ) and Patient-Centered Outcomes Research Institute (PCORI), grant K12HS026379 (Christopher J. Tignanelli), the Minnesota Learning Health System Mentored Training Program (MH-LHS), M Health Fairview Institutional Funds (Carolyn T. Bramante), the National Center for Advancing Translational Sciences, grants KL2TR002492 and UL1TR002494 (Carolyn T. Bramante), the National Heart, Lung, Blood Institute T32HL07741 (Nicholas E. Ingraham), COVID-19 rapid response grant UM 2020-2231. The work was supported by the University of Minnesota Institute for Engineering in Medicine Medtronic Professorship held by David J. Odde, and a COVID-19 rapid response grant to David J. Odde from the University of Minnesota Medical School, as well as the National Institute of Health, grant U54-CA210190 (David J. Odde). Publisher Copyright: {\textcopyright} 2020 Wiley Periodicals LLC",

year = "2020",

month = dec,

day = "17",

doi = "10.1002/jmv.26728",

language = "English (US)",

volume = "93",

pages = "1843--1846",

journal = "Journal of Medical Virology",

issn = "0146-6615",

publisher = "John Wiley and Sons Inc.",

number = "4",

}

TY - JOUR

T1 - mTOR inhibition in COVID-19

T2 - A commentary and review of efficacy in RNA viruses

AU - Karam, Basil S.

AU - Morris, Rachel S.

AU - Bramante, Carolyn T.

AU - Puskarich, Michael

AU - Zolfaghari, Emily J.

AU - Lotfi-Emran, Sahar

AU - Ingraham, Nicholas E.

AU - Charles, Anthony

AU - Odde, David J.

AU - Tignanelli, Christopher J.

N1 - Funding Information: This study was supported by the Agency for Healthcare Research and Quality (AHRQ) and Patient‐Centered Outcomes Research Institute (PCORI), grant K12HS026379 (Christopher J. Tignanelli), the Minnesota Learning Health System Mentored Training Program (MH‐LHS), M Health Fairview Institutional Funds (Carolyn T. Bramante), the National Center for Advancing Translational Sciences, grants KL2TR002492 and UL1TR002494 (Carolyn T. Bramante), the National Heart, Lung, Blood Institute T32HL07741 (Nicholas E. Ingraham), COVID‐19 rapid response grant UM 2020‐2231. The work was supported by the University of Minnesota Institute for Engineering in Medicine Medtronic Professorship held by David J. Odde, and a COVID‐19 rapid response grant to David J. Odde from the University of Minnesota Medical School, as well as the National Institute of Health, grant U54‐CA210190 (David J. Odde). Funding Information: This study was supported by the Agency for Healthcare Research and Quality (AHRQ) and Patient-Centered Outcomes Research Institute (PCORI), grant K12HS026379 (Christopher J. Tignanelli), the Minnesota Learning Health System Mentored Training Program (MH-LHS), M Health Fairview Institutional Funds (Carolyn T. Bramante), the National Center for Advancing Translational Sciences, grants KL2TR002492 and UL1TR002494 (Carolyn T. Bramante), the National Heart, Lung, Blood Institute T32HL07741 (Nicholas E. Ingraham), COVID-19 rapid response grant UM 2020-2231. The work was supported by the University of Minnesota Institute for Engineering in Medicine Medtronic Professorship held by David J. Odde, and a COVID-19 rapid response grant to David J. Odde from the University of Minnesota Medical School, as well as the National Institute of Health, grant U54-CA210190 (David J. Odde). Publisher Copyright: © 2020 Wiley Periodicals LLC

PY - 2020/12/17

Y1 - 2020/12/17

N2 - In this commentary, we shed light on the role of the mammalian target of rapamycin (mTOR) pathway in viral infections. The mTOR pathway has been demonstrated to be modulated in numerous RNA viruses. Frequently, inhibiting mTOR results in suppression of virus growth and replication. Recent evidence points towards modulation of mTOR in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We discuss the current literature on mTOR in SARS-CoV-2 and highlight evidence in support of a role for mTOR inhibitors in the treatment of coronavirus disease 2019.

AB - In this commentary, we shed light on the role of the mammalian target of rapamycin (mTOR) pathway in viral infections. The mTOR pathway has been demonstrated to be modulated in numerous RNA viruses. Frequently, inhibiting mTOR results in suppression of virus growth and replication. Recent evidence points towards modulation of mTOR in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We discuss the current literature on mTOR in SARS-CoV-2 and highlight evidence in support of a role for mTOR inhibitors in the treatment of coronavirus disease 2019.

KW - COVID-19

KW - mTOR

KW - mTORi

UR - http://www.scopus.com/inward/record.url?scp=85097604434&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85097604434&partnerID=8YFLogxK

U2 - 10.1002/jmv.26728

DO - 10.1002/jmv.26728

M3 - Comment/debate

C2 - 33314219

AN - SCOPUS:85097604434

SN - 0146-6615

VL - 93

SP - 1843

EP - 1846

JO - Journal of Medical Virology

JF - Journal of Medical Virology

IS - 4

ER -

mTOR inhibition in COVID-19: A commentary and review of efficacy in RNA viruses

Abstract

Bibliographical note

Keywords

PubMed: MeSH publication types

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this